Skip to content
DataLookout
Menu

NCT05629442

ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

StatusWithdrawn
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: Funding issues Show 4 more changesShow less
    • Enrollment target: estimated 60 to confirmed 0
    • Eligibility criteria expanded, about 10 words
    • Study sites: 2 to 0
    • Secondary endpoints: details revised at 8 of 10 entries
  2. Minor Site details revised at 1 of 2 sitesv3
  3. Notable Primary completion date: Jun 2026 to Jun 2028
    • Start date: Jan 2023 to Oct 1, 2026
    • Site contacts updated at 2 of 2 sites
    • Collaborators: 2 to 1
    v2
  4. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Rate of successful non-operative management
Timeframe: 1 year
Rate of successful pathologic complete response
Timeframe: 1 year

Secondary (10)

Rate of local recurrence
EORTC-QLQ-CR 29 questionnaire
FACT-C questionnaire
IADL Scale
Brief Pain Inventory (BPI) questionnaire
Show 5 moreShow less
Bowel function assessment with LARS score
Bowel function assessment with FISI score
Bowel function assessment with FIQOL score
Disease-free survival (DFS)
Overall Survival (OS)

Arms and interventions

EVALUATION OF CTDNA

This prospective observational, non-therapeutic study will enroll patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy/ All procedures involved with this trial will be done as per standard of care \- Except for the initial research biopsy, quality of life assessments and ctDNA collection

Other: ctDNA